Form 4 for MLTX MoonLake Immunotherapeutics

Accepted 2026-06-18 18:45:08 ET · period of report 2026-06-17 · accession 0001213900-26-070259 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MT	2026-06-18 18:45	2026-06-17+	MLTX	Bodenstedt Matthias	CFO	S - Sale	$19.67	-17.9K	1.15M	-2%	-$351.6K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A ordinary shares, par value $0.0001 per share	2026-06-17	S	D	15,082	$19.68	1,157,349	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2	Common	Class A ordinary shares, par value $0.0001 per share	2026-06-18	S	D	2,794	$19.60	1,154,555	D	—	—	(F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.